Summary of Limitations

• Risk ratio is not constant over time,

• Not enough data over 6 month

• Inadequate sample size outside VIGOR for rofecoxib 50 mg …...

• Pooling different dose levels is problematic for an evaluation of rofecoxib 50 mg

Previous slide

Next slide

Back to first slide

View graphic version